Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ampicillin + gentamicin + clindamycin is a combination of three antibiotics commonly used for the treatment of severe or complicated infections, particularly in pediatric and obstetric settings. This regimen is frequently employed for conditions such as complicated appendicitis in children and peripartum or intra-abdominal infections. - Ampicillin is a beta-lactam antibiotic (aminopenicillin) that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. - Gentamicin is an aminoglycoside antibiotic that binds to the 30S subunit of bacterial ribosomes, causing misreading of mRNA and inhibition of protein synthesis. - Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 23S rRNA of the 50S ribosomal subunit. This triple therapy provides broad-spectrum coverage against gram-positive bacteria (including anaerobes), gram-negative bacteria, and some anaerobic organisms. It has been shown to be effective in treating serious mixed aerobic/anaerobic infections[2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ampicillin + gentamicin + clindamycin.